chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site erythema, Vaccination site pain, Vaccination site swelling
Clinical narrative: Injection site pain; injection site redness; Injection site swelling; This spontaneous case was reported by a nurse and describes the occurrence of VACCINATION SITE PAIN (Injection site pain), VACCINATION SITE ERYTHEMA (injection site redness) and VACCINATION SITE SWELLING (Injection site swelling) in a 30-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011J20A) for COVID-19 vaccination.     Concurrent medical conditions included Penicillin allergy.    On 09-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 16-Mar-2021, the patient experienced VACCINATION SITE PAIN (Injection site pain), VACCINATION SITE ERYTHEMA (injection site redness) and VACCINATION SITE SWELLING (Injection site swelling). At the time of the report, VACCINATION SITE PAIN (Injection site pain), VACCINATION SITE ERYTHEMA (injection site redness) and VACCINATION SITE SWELLING (Injection site swelling) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered VACCINATION SITE PAIN (Injection site pain), VACCINATION SITE ERYTHEMA (injection site redness) and VACCINATION SITE SWELLING (Injection site swelling) to be related.    Concomitant product use was not provided by the reporter.  Treatment information was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 06-May-2021: Initial additional included patient demographic details, allergy history, route of vaccine administration and event outcome.
Age: 17.0
Sex: F
Vaccine: COVID19
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: 17 year old female who received her first dose of the Moderna COVID19 vaccine; This spontaneous case was reported by a nurse and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (17 year old female who received her first dose of the Moderna COVID19 vaccine) in a 17-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 006B21A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (Medical history not provided.).    On 16-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 16-Mar-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (17 year old female who received her first dose of the Moderna COVID19 vaccine). On 16-Mar-2021, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (17 year old female who received her first dose of the Moderna COVID19 vaccine) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   This report refers to a case of product administered to patient of inappropriate age for mRNA-1273, lot # 006B21A with no associated AEs.; Sender's Comments: This report refers to a case of product administered to patient of inappropriate age for mRNA-1273, lot # 006B21A with no associated AEs.
Sex: F
Vaccine: COVID19
Symptoms: Palpitations
Clinical narrative: Heart palpitations; This spontaneous case was reported by a consumer and describes the occurrence of PALPITATIONS (Heart palpitations) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Nervous (Before taking the vaccine) and Anxiety attack (Before taking the vaccine).    On 16-Mar-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 16-Mar-2021, the patient experienced PALPITATIONS (Heart palpitations). At the time of the report, PALPITATIONS (Heart palpitations) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter. Treatment information was not provided/unknown.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Headache, Nausea, Pain in extremity, Vaccination site erythema
Clinical narrative: vertigo; dizziness; nausea; vomiting; Headache; Vaccination site erythema; Vaccination site swelling; Pain in arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Pain in arm ), VERTIGO (vertigo), DIZZINESS (dizziness), VACCINATION SITE ERYTHEMA (Vaccination site erythema) and VACCINATION SITE SWELLING (Vaccination site swelling) in a 63-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 032M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Vertigo (doctor told her that it´s on her mid ear). Concomitant products included VITAMIN C [ASCORBIC ACID] and ZINC for an unknown indication.    On 13-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Mar-2021, the patient experienced PAIN IN EXTREMITY (Pain in arm ). On 15-Mar-2021, the patient experienced VACCINATION SITE ERYTHEMA (Vaccination site erythema) and VACCINATION SITE SWELLING (Vaccination site swelling). On 16-Mar-2021, the patient experienced VERTIGO (vertigo), DIZZINESS (dizziness), NAUSEA (nausea), VOMITING (vomiting) and HEADACHE (Headache). At the time of the report, PAIN IN EXTREMITY (Pain in arm ), VERTIGO (vertigo), DIZZINESS (dizziness), VACCINATION SITE SWELLING (Vaccination site swelling), NAUSEA (nausea), VOMITING (vomiting) and HEADACHE (Headache) outcome was unknown and VACCINATION SITE ERYTHEMA (Vaccination site erythema) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       The concomitant medications were discontinued last week. The patient's second dose was scheduled on 10-Apr-2021.  The patient's redness disappeared. Reportedly, the vertigo is 50% more intense.  No treatment information was provided by the reporter.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site swelling, Vertigo, Vomiting
Clinical narrative: vertigo; dizziness; nausea; vomiting; Headache; Vaccination site erythema; Vaccination site swelling; Pain in arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Pain in arm ), VERTIGO (vertigo), DIZZINESS (dizziness), VACCINATION SITE ERYTHEMA (Vaccination site erythema) and VACCINATION SITE SWELLING (Vaccination site swelling) in a 63-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 032M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Vertigo (doctor told her that it´s on her mid ear). Concomitant products included VITAMIN C [ASCORBIC ACID] and ZINC for an unknown indication.    On 13-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Mar-2021, the patient experienced PAIN IN EXTREMITY (Pain in arm ). On 15-Mar-2021, the patient experienced VACCINATION SITE ERYTHEMA (Vaccination site erythema) and VACCINATION SITE SWELLING (Vaccination site swelling). On 16-Mar-2021, the patient experienced VERTIGO (vertigo), DIZZINESS (dizziness), NAUSEA (nausea), VOMITING (vomiting) and HEADACHE (Headache). At the time of the report, PAIN IN EXTREMITY (Pain in arm ), VERTIGO (vertigo), DIZZINESS (dizziness), VACCINATION SITE SWELLING (Vaccination site swelling), NAUSEA (nausea), VOMITING (vomiting) and HEADACHE (Headache) outcome was unknown and VACCINATION SITE ERYTHEMA (Vaccination site erythema) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       The concomitant medications were discontinued last week. The patient's second dose was scheduled on 10-Apr-2021.  The patient's redness disappeared. Reportedly, the vertigo is 50% more intense.  No treatment information was provided by the reporter.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site erythema, Vaccination site pain, Vaccination site pruritus, Vaccination site swelling
Clinical narrative: Itching at the injection site/Injection site pain/swelling/redness/itchy; pain at the injection site/Injection site pain/swelling/redness/itchy; Swelling at the injection site/Injection site pain/swelling/redness/itchy; Redness at the injection site/Injection site pain/swelling/redness/itchy; This spontaneous case was reported by a nurse and describes the occurrence of VACCINATION SITE PRURITUS (Itching at the injection site/Injection site pain/swelling/redness/itchy), VACCINATION SITE PAIN (pain at the injection site/Injection site pain/swelling/redness/itchy), VACCINATION SITE SWELLING (Swelling at the injection site/Injection site pain/swelling/redness/itchy) and VACCINATION SITE ERYTHEMA (Redness at the injection site/Injection site pain/swelling/redness/itchy) in a 32-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011J20A) for COVID-19 vaccination.     No Medical History information was reported.    On 04-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In March 2021, the patient experienced VACCINATION SITE PRURITUS (Itching at the injection site/Injection site pain/swelling/redness/itchy), VACCINATION SITE PAIN (pain at the injection site/Injection site pain/swelling/redness/itchy), VACCINATION SITE SWELLING (Swelling at the injection site/Injection site pain/swelling/redness/itchy) and VACCINATION SITE ERYTHEMA (Redness at the injection site/Injection site pain/swelling/redness/itchy). At the time of the report, VACCINATION SITE PRURITUS (Itching at the injection site/Injection site pain/swelling/redness/itchy), VACCINATION SITE PAIN (pain at the injection site/Injection site pain/swelling/redness/itchy), VACCINATION SITE SWELLING (Swelling at the injection site/Injection site pain/swelling/redness/itchy) and VACCINATION SITE ERYTHEMA (Redness at the injection site/Injection site pain/swelling/redness/itchy) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Treatment drugs were not provided concomitant drugs were not provided   Most recent FOLLOW-UP information incorporated above includes: On 24-May-2021: Completed ADR Form
Age: 54.0
Sex: F
Vaccine: COVID19
Symptoms: Rash macular, Vaccination site pain, Vaccination site pruritus, Vaccination site rash, Vaccination site swelling
Clinical narrative: Red blotch at site of injection; Itchy at site of injection; Raised area (bigger than a half-dollar) at site of injection; Burning sensation at site of injection; Raised area (bigger than a half-dollar) at site of injection; This spontaneous case was reported by a consumer and describes the occurrence of RASH MACULAR (Red blotch at site of injection), VACCINATION SITE PRURITUS (Itchy at site of injection), VACCINATION SITE SWELLING (Raised area (bigger than a half-dollar) at site of injection), VACCINATION SITE PAIN (Burning sensation at site of injection) and VACCINATION SITE RASH (Raised area (bigger than a half-dollar) at site of injection) in a 54-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 029L20A) for COVID-19 vaccination.     Concurrent medical conditions included Poison ivy rash.    On 09-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Mar-2021, the patient experienced RASH MACULAR (Red blotch at site of injection), VACCINATION SITE PRURITUS (Itchy at site of injection), VACCINATION SITE SWELLING (Raised area (bigger than a half-dollar) at site of injection), VACCINATION SITE PAIN (Burning sensation at site of injection) and VACCINATION SITE RASH (Raised area (bigger than a half-dollar) at site of injection). The patient was treated with HYDROCORTISONE for Vaccination site pruritus, at an unspecified dose and frequency. At the time of the report, RASH MACULAR (Red blotch at site of injection), VACCINATION SITE PRURITUS (Itchy at site of injection), VACCINATION SITE SWELLING (Raised area (bigger than a half-dollar) at site of injection), VACCINATION SITE PAIN (Burning sensation at site of injection) and VACCINATION SITE RASH (Raised area (bigger than a half-dollar) at site of injection) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.  On 09-Mar-2021, the patient developed a red blotch, raised (bigger than half-dollar) area, burning sensation, itchy. On 11-Mar-2021, symptoms disappeared. On 16-Mar-2021, developed another red blotch (more red than previous reaction), raised area, itchy, all at site of injection. Treatment with hydrocortisone cream was given and some symptoms resolved. On 17-Mar-2021 symptoms still persist.   This case was linked to MOD-2021-109664 (Patient Link).
Age: 25.0
Sex: M
Vaccine: COVID19
Symptoms: Lymphadenopathy
Clinical narrative: swollen lymph nodes in his neck; This spontaneous case was reported by a nurse and describes the occurrence of LYMPHADENOPATHY (swollen lymph nodes in his neck) in a 25-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011J20A) for COVID-19 vaccination.     No Medical History information was reported.    On 11-Mar-2021 at 2:40 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Mar-2021 at 8:00 PM, the patient experienced LYMPHADENOPATHY (swollen lymph nodes in his neck). At the time of the report, LYMPHADENOPATHY (swollen lymph nodes in his neck) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications reported by investigator No treatment medications provided by the reporter.   Most recent FOLLOW-UP information incorporated above includes: On 24-May-2021: Additional document received on 24 May 2021. Reporter contact details updated, patient demographics updated and route of administration of vaccine added.
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Vaccination site burning; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (Vaccination site burning) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 16-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE PAIN (Vaccination site burning). At the time of the report, VACCINATION SITE PAIN (Vaccination site burning) outcome was unknown.            The  concomitant medications on use were not provided.  No laboratory data was provided.   No treatment information was provided.
Sex: F
Vaccine: COVID19
Symptoms: Myalgia, Vaccination site erythema, Vaccination site pain, Vaccination site swelling
Clinical narrative: Pain, redness and swelling at the injection site; Pain, redness and swelling at the injection site; Pain, redness and swelling at the injection site; Muscle pain; This spontaneous case was reported by a nurse and describes the occurrence of VACCINATION SITE PAIN (Pain, redness and swelling at the injection site), VACCINATION SITE ERYTHEMA (Pain, redness and swelling at the injection site), VACCINATION SITE SWELLING (Pain, redness and swelling at the injection site) and MYALGIA (Muscle pain) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011J20A) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Mar-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-Mar-2021, the patient experienced VACCINATION SITE PAIN (Pain, redness and swelling at the injection site), VACCINATION SITE ERYTHEMA (Pain, redness and swelling at the injection site), VACCINATION SITE SWELLING (Pain, redness and swelling at the injection site) and MYALGIA (Muscle pain). At the time of the report, VACCINATION SITE PAIN (Pain, redness and swelling at the injection site), VACCINATION SITE ERYTHEMA (Pain, redness and swelling at the injection site), VACCINATION SITE SWELLING (Pain, redness and swelling at the injection site) and MYALGIA (Muscle pain) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were provided.  No treatment information was mentioned.
Age: 62.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: dose of the vaccine in his left arm 6 hours after first vial puncture; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (dose of the vaccine in his left arm 6 hours after first vial puncture) in a 62-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 16-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 16-Mar-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (dose of the vaccine in his left arm 6 hours after first vial puncture). On 16-Mar-2021, EXPIRED PRODUCT ADMINISTERED (dose of the vaccine in his left arm 6 hours after first vial puncture) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter.  Treatment information was not provided by the reporter.
Sex: M
Vaccine: COVID19
Symptoms: Dose calculation error, Insomnia, Pain
Clinical narrative: administration high in his left arm, right in joint between arm and shoulder; no able to sleep at night; Hurts like hell; touch is hurting; This spontaneous case was reported by a consumer and describes the occurrence of DOSE CALCULATION ERROR (administration high in his left arm, right in joint between arm and shoulder), INSOMNIA (no able to sleep at night), PAIN (Hurts like hell) and PAIN (touch is hurting) in a 70-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 25-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Jan-2021, the patient experienced DOSE CALCULATION ERROR (administration high in his left arm, right in joint between arm and shoulder), INSOMNIA (no able to sleep at night), PAIN (Hurts like hell) and PAIN (touch is hurting). At the time of the report, DOSE CALCULATION ERROR (administration high in his left arm, right in joint between arm and shoulder) had resolved and INSOMNIA (no able to sleep at night), PAIN (Hurts like hell) and PAIN (touch is hurting) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were provided No treatment medications were provided
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Urinary tract infection
Clinical narrative: This spontaneous case reported by a consumer, describes the occurrence of urinary tract infection (UTI) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 vaccine, batch# 015M20A) for COVID-19 immunization. The patient's past medical history included UTI (a week before first dose had a UTI). Concomitant products included ciprofloxacin for UTI, Synthroid (levothyroxine sodium) for an unknown indication. On Feb 18, 2021, patient received first dose of mRNA-1273 (Moderna COVID-19 vaccine), unknown route; 1 dosage form. On an unknown date, patient experienced urinary tract infection (UTI). At the time of the report, urinary tract infection (UTI) outcome: unknown. The action taken with mRNA-1273 (Moderna COVID-19 vaccine): unknown. Reportedly, patient is taking a strong medication (unspecified) for UTI.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site erythema, Vaccination site pruritus, Vaccination site rash, Vaccination site swelling
Clinical narrative: red at the injection site; puffed out a little bit; itchy; back red at the injection site; like a rash; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PRURITUS (itchy), VACCINATION SITE ERYTHEMA (red at the injection site), VACCINATION SITE RASH (like a rash), VACCINATION SITE SWELLING (puffed out a little bit) and VACCINATION SITE ERYTHEMA (back red at the injection site) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 003A21A) for COVID-19 vaccination.     No medical history information was reported.  Concomitant products included ATORVASTATIN for an unknown indication.    On 08-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Mar-2021, the patient experienced VACCINATION SITE RASH (like a rash) and VACCINATION SITE ERYTHEMA (back red at the injection site). On 15-Mar-2021, the patient experienced VACCINATION SITE PRURITUS (itchy). On an unknown date, the patient experienced VACCINATION SITE ERYTHEMA (red at the injection site) and VACCINATION SITE SWELLING (puffed out a little bit). At the time of the report, VACCINATION SITE PRURITUS (itchy), VACCINATION SITE ERYTHEMA (red at the injection site), VACCINATION SITE RASH (like a rash) and VACCINATION SITE SWELLING (puffed out a little bit) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment medication was reported. For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments. The patient reported, it was red for a few days after the shot, but then it went away. On 14-Mar-2021, it was back, red at the injection site. It is like a rash, it is puffed out a little bit. On 15-Mar-2021, it was a little bit bigger, and then it started to get itchy, It was also bigger since then.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Magnetic resonance imaging, Rhinorrhoea, Upper-airway cough syndrome
Clinical narrative: Drippage that causes sore throat; Fatigue; Running/runny nose; This spontaneous case was reported by a health care professional and describes the occurrence of RHINORRHOEA (Running/runny nose), UPPER-AIRWAY COUGH SYNDROME (Drippage that causes sore throat) and FATIGUE (Fatigue) in a 36-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 028L20A) for COVID-19 vaccination.     The patient's past medical history included Stroke (Stroke x2) on 30-May-2016. Previously administered products included for an unreported indication: FLU in October 2020. Family history included Cancer (Mother), Diabetes (Father) and Blood pressure high (Father). Concurrent medical conditions included Seasonal allergy since 01-Jan-2012. Concomitant products included CITALOPRAM HYDROBROMIDE (CELEXA [CITALOPRAM HYDROBROMIDE]) for Anxiety, TOPIRAMATE (TOPAMAX) and ACETYLSALICYLIC ACID (BABY ASPIRIN) for Stroke.    On 15-Jan-2021 at 11:00 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 16-Jan-2021, the patient experienced RHINORRHOEA (Running/runny nose). On an unknown date, the patient experienced UPPER-AIRWAY COUGH SYNDROME (Drippage that causes sore throat). an unknown date, the patient experienced FATIGUE (Fatigue). At the time of the report, RHINORRHOEA (Running/runny nose) and UPPER-AIRWAY COUGH SYNDROME (Drippage that causes sore throat) had not resolved and FATIGUE (Fatigue) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In 2016, Magnetic resonance imaging: stroke (Inconclusive) MRI around "my strokes" and every year after.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   A self-report from a female health care professional was forwarded by Pfizer regarding the following reported events: Running nose (day after shot, also reported as 24-Jan-2021), drippage that caused sore throat (starting 2-3 days after vaccination) and fatigue. The patient reported that she went to Urgent Care and "believed it was a viral infection". Treatment information was not provided. The patient reported that her next dose of the Moderna vaccine was scheduled for 12-Feb-2021.
Sex: F
Vaccine: COVID19
Symptoms: Nausea
Clinical narrative: nauseated; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by an other and describes the occurrence of NAUSEA (nauseated) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 immunization.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) at an unspecified dose. On an unknown date, the patient experienced NAUSEA (nauseated). At the time of the report, NAUSEA (nauseated) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications reported by investigator No treatment medications provided by the reporter.   Reporter did not allow further contact
Sex: F
Vaccine: COVID19
Symptoms: Back pain, Headache, Neck pain
Clinical narrative: Pain in the back of neck; Pain in lower back; Pain in forehead; This spontaneous case was reported by an other and describes the occurrence of NECK PAIN (Pain in the back of neck), BACK PAIN (Pain in lower back) and HEADACHE (Pain in forehead) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced NECK PAIN (Pain in the back of neck), BACK PAIN (Pain in lower back) and HEADACHE (Pain in forehead). The patient was treated with SEMAGLUTIDE (OZEMPIC) ongoing since an unknown date for Pain, at an unspecified dose and frequency. At the time of the report, NECK PAIN (Pain in the back of neck), BACK PAIN (Pain in lower back) and HEADACHE (Pain in forehead) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
Sex: U
Vaccine: COVID19
Symptoms: Chills, Decreased appetite, Dizziness, Fatigue, Nausea
Clinical narrative: Severe sore arm pain; Loss of appetite; Fatigue, dizziness, tiredness and chills; Fatigue, dizziness, tiredness and chills; Fatigue, dizziness, tiredness and chills; Nausea; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Severe sore arm pain), DECREASED APPETITE (Loss of appetite), DIZZINESS (Fatigue, dizziness, tiredness and chills), FATIGUE (Fatigue, dizziness, tiredness and chills) and CHILLS (Fatigue, dizziness, tiredness and chills) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Diabetes.   In February 2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In February 2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (Severe sore arm pain), DECREASED APPETITE (Loss of appetite), DIZZINESS (Fatigue, dizziness, tiredness and chills), FATIGUE (Fatigue, dizziness, tiredness and chills), CHILLS (Fatigue, dizziness, tiredness and chills) and NAUSEA (Nausea). At the time of the report, PAIN IN EXTREMITY (Severe sore arm pain), DECREASED APPETITE (Loss of appetite), DIZZINESS (Fatigue, dizziness, tiredness and chills), FATIGUE (Fatigue, dizziness, tiredness and chills), CHILLS (Fatigue, dizziness, tiredness and chills) and NAUSEA (Nausea) had not resolved.            Reporter did not allow further contact
Sex: U
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: Severe sore arm pain; Loss of appetite; Fatigue, dizziness, tiredness and chills; Fatigue, dizziness, tiredness and chills; Fatigue, dizziness, tiredness and chills; Nausea; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Severe sore arm pain), DECREASED APPETITE (Loss of appetite), DIZZINESS (Fatigue, dizziness, tiredness and chills), FATIGUE (Fatigue, dizziness, tiredness and chills) and CHILLS (Fatigue, dizziness, tiredness and chills) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Diabetes.   In February 2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In February 2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (Severe sore arm pain), DECREASED APPETITE (Loss of appetite), DIZZINESS (Fatigue, dizziness, tiredness and chills), FATIGUE (Fatigue, dizziness, tiredness and chills), CHILLS (Fatigue, dizziness, tiredness and chills) and NAUSEA (Nausea). At the time of the report, PAIN IN EXTREMITY (Severe sore arm pain), DECREASED APPETITE (Loss of appetite), DIZZINESS (Fatigue, dizziness, tiredness and chills), FATIGUE (Fatigue, dizziness, tiredness and chills), CHILLS (Fatigue, dizziness, tiredness and chills) and NAUSEA (Nausea) had not resolved.            Reporter did not allow further contact
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Back pain, Chills, Vaccination complication
Clinical narrative: This spontaneous case reported by an other healthcare professional, describes the occurrence of back pain, vaccination complication (drug side effect) and chills in a 58-year-old female patient who received mRNA-1273 (Moderna COVID-19 vaccine) for COVID-19 immunization. Co-suspect product included adalimumab injection for psoriatic arthritis. No medical history reported. On an unknown date, patient received first dose of mRNA-1273 (Moderna COVID-19 vaccine), intramuscular; 1 dosage form and adalimumab (unknown route) 1 dosage form. On an unknown date, patient experienced back pain, vaccination complication (drug side effect) and chills. At the time of the report, back pain and vaccination complication (drug side effect): not resolved and chills outcome: unknown. The action taken with mRNA-1273 (Moderna COVID-19 vaccine), intramuscular: unknown. No treatment information provided. Most recent follow-up information incorporated above includes: On May 3, 2021: No new information provided.
Age: 69.0
Sex: M
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: Left arm was sore; This spontaneous case was reported by an other health care professional and describes the occurrence of PAIN IN EXTREMITY (Left arm was sore) in a 69-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Ankylosing spondylitis.    No Medical History information was reported.   In February 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. In February 2021, the patient experienced PAIN IN EXTREMITY (Left arm was sore). In February 2021, PAIN IN EXTREMITY (Left arm was sore) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter.  Treatment information was not provided.
Age: 43.0
Sex: F
Vaccine: COVID19, UNK
Symptoms: Headache
Clinical narrative: occasional headaches; This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (occasional headaches) in a 43-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product TREPROSTINIL SODIUM for Pulmonary arterial hypertension.    Concurrent medical conditions included Pulmonary arterial hypertension. Concomitant products included APIXABAN (ELIQUIS) for an unknown indication.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. and TREPROSTINIL SODIUM (IV drip) .165 microgram/kilogram. On an unknown date, the patient experienced HEADACHE (occasional headaches). At the time of the report, HEADACHE (occasional headaches) outcome was unknown.            No treatment medication was reported.   Reporter did not allow further contact
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal X-ray, Computerised tomogram, Fatigue, Glycosylated haemoglobin, Headache
Clinical narrative: Fatigue; Vaccination site pain; Headache; This spontaneous case was reported by an other health care professional and describes the occurrence of FATIGUE (Fatigue), VACCINATION SITE PAIN (Vaccination site pain) and HEADACHE (Headache) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 042L20A and 037KZ0A) for COVID-19 vaccination.     The patient's past medical history included Cyst ovary from April 2020 to September 2020, Appendicitis in January 2015, General physical condition abnormal in 2012, Weight gain in 2012, Diabetes since 2016, Fatty liver, Elevated liver enzymes in 2017, Psoriasis in 2016, Shingles from November 2020 to December 2020 and Alcohol use (Abstain from alcohol). Concurrent medical conditions included Drug allergy (Sulfa drug allergy associated with manifestations of itching and burning skin.). Concomitant products included ADALIMUMAB (HUMIRA) for Crohn's disease, METHOTREXATE for Psoriasis, LIDOCAINE and DOXYCYCLINE for an unknown indication.   On 30-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 27-Jan-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 30-Dec-2020, the patient experienced FATIGUE (Fatigue), VACCINATION SITE PAIN (Vaccination site pain) and HEADACHE (Headache). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency and METFORMIN at an unspecified dose and frequency. On 03-Jan-2021, FATIGUE (Fatigue), VACCINATION SITE PAIN (Vaccination site pain) and HEADACHE (Headache) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In 2012, Weight: inconclusive (Inconclusive) Inconclusive. In January 2015, Abdominal X-ray: inconclusive (Inconclusive) Inconclusive. In January 2015, Computerised tomogram: inconclusive (Inconclusive) Inconclusive. In 2016, Glycosylated haemoglobin: inconclusive (Inconclusive) Inconclusive. On 13-Nov-2020, Ultrasound liver: inconclusive (Inconclusive) Inconclusive.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Treatment for the event included TYLENOL, METFORMIN and BYDUREON BCISE.  The patient received both scheduled doses of mRNA-1273 prior to the events; therefore, action taken with the drug in response to the events are not applicable.   This case was linked to MOD-2021-047583 (Patient Link).
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Ultrasound liver, Vaccination site pain, Weight
Clinical narrative: Fatigue; Vaccination site pain; Headache; This spontaneous case was reported by an other health care professional and describes the occurrence of FATIGUE (Fatigue), VACCINATION SITE PAIN (Vaccination site pain) and HEADACHE (Headache) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 042L20A and 037KZ0A) for COVID-19 vaccination.     The patient's past medical history included Cyst ovary from April 2020 to September 2020, Appendicitis in January 2015, General physical condition abnormal in 2012, Weight gain in 2012, Diabetes since 2016, Fatty liver, Elevated liver enzymes in 2017, Psoriasis in 2016, Shingles from November 2020 to December 2020 and Alcohol use (Abstain from alcohol). Concurrent medical conditions included Drug allergy (Sulfa drug allergy associated with manifestations of itching and burning skin.). Concomitant products included ADALIMUMAB (HUMIRA) for Crohn's disease, METHOTREXATE for Psoriasis, LIDOCAINE and DOXYCYCLINE for an unknown indication.   On 30-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 27-Jan-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 30-Dec-2020, the patient experienced FATIGUE (Fatigue), VACCINATION SITE PAIN (Vaccination site pain) and HEADACHE (Headache). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency and METFORMIN at an unspecified dose and frequency. On 03-Jan-2021, FATIGUE (Fatigue), VACCINATION SITE PAIN (Vaccination site pain) and HEADACHE (Headache) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In 2012, Weight: inconclusive (Inconclusive) Inconclusive. In January 2015, Abdominal X-ray: inconclusive (Inconclusive) Inconclusive. In January 2015, Computerised tomogram: inconclusive (Inconclusive) Inconclusive. In 2016, Glycosylated haemoglobin: inconclusive (Inconclusive) Inconclusive. On 13-Nov-2020, Ultrasound liver: inconclusive (Inconclusive) Inconclusive.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Treatment for the event included TYLENOL, METFORMIN and BYDUREON BCISE.  The patient received both scheduled doses of mRNA-1273 prior to the events; therefore, action taken with the drug in response to the events are not applicable.   This case was linked to MOD-2021-047583 (Patient Link).
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Oral herpes
Clinical narrative: Fever blister; This spontaneous case was reported by a consumer and describes the occurrence of ORAL HERPES (Fever blister) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Multiple sclerosis relapse. Concomitant products included OCRELIZUMAB (OCREVUS) for an unknown indication.    On 25-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 26-Jan-2021, the patient experienced ORAL HERPES (Fever blister). At the time of the report, ORAL HERPES (Fever blister) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Treatment information was not provided by the reporter.
Sex: F
Vaccine: COVID19
Symptoms: Hypersensitivity, Injection site mass, Malaise
Clinical narrative: This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of MALAISE (violently sick), INJECTION SITE MASS (golfball sized lump on her arm at the injection site) and HYPERSENSITIVITY (allergic reaction) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced MALAISE (violently sick), INJECTION SITE MASS (golfball sized lump on her arm at the injection site) and HYPERSENSITIVITY (allergic reaction). At the time of the report, MALAISE (violently sick), INJECTION SITE MASS (golfball sized lump on her arm at the injection site) and HYPERSENSITIVITY (allergic reaction) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Treatment medicines were not reported
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Oral herpes, Vaccination site erythema, Vaccination site rash, Vaccination site warmth
Clinical narrative: warm at the injection site; fever blister; rash at the injection site; red circle at the injection site,redness at the injection; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 17-Mar-2021 and was forwarded to Moderna on 17-Mar-2021.    This spontaneous case was reported by a consumer and describes the occurrence of ORAL HERPES (fever blister), VACCINATION SITE WARMTH (warm at the injection site), VACCINATION SITE RASH (rash at the injection site) and VACCINATION SITE ERYTHEMA (red circle at the injection site,redness at the injection) in a 64-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027A21A) for COVID-19 vaccination.     No reported medical history.  Concomitant products included HYDROCHLOROTHIAZIDE, LOSARTAN POTASSIUM (HYDROCHLOROTHIAZIDE + LOSARTAN) and LEVOTHYROXINE for an unknown indication.    On 07-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-Mar-2021, the patient experienced VACCINATION SITE RASH (rash at the injection site) and VACCINATION SITE ERYTHEMA (red circle at the injection site,redness at the injection). On 12-Mar-2021, the patient experienced ORAL HERPES (fever blister). On 15-Mar-2021, the patient experienced VACCINATION SITE WARMTH (warm at the injection site). At the time of the report, ORAL HERPES (fever blister), VACCINATION SITE WARMTH (warm at the injection site), VACCINATION SITE RASH (rash at the injection site) and VACCINATION SITE ERYTHEMA (red circle at the injection site,redness at the injection) had not resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment information in response to events was not provided.
Sex: M
Vaccine: COVID19
Symptoms: Paraesthesia
Clinical narrative: tingling on his back; This spontaneous case was reported by an other health care professional and describes the occurrence of PARAESTHESIA (tingling on his back) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 16-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 17-Mar-2021, the patient experienced PARAESTHESIA (tingling on his back). At the time of the report, PARAESTHESIA (tingling on his back) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No Treatment medications were provided No  Concomitant medications were provided; Sender's Comments: Very limited information regarding this event/s has been provided at this time.  Further information has been requested.
Age: 76.0
Sex: M
Vaccine: COVID19
Symptoms: Blood glucose fluctuation, Headache, Influenza like illness
Clinical narrative: blood sugar fluctuated and became unmanageable; flu like symptoms; headache; This spontaneous case was reported by a consumer and describes the occurrence of BLOOD GLUCOSE FLUCTUATION (blood sugar fluctuated and became unmanageable), INFLUENZA LIKE ILLNESS (flu like symptoms) and HEADACHE (headache) in a 76-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 31A21A) for COVID-19 vaccination.    Co-suspect product included non-company product OXYCODONE for an unknown indication.    Concurrent medical conditions included Diabetes mellitus. Concomitant products included INSULIN for Blood sugar level fluctuation.   On 12-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient started OXYCODONE (unknown route) 1 dosage form. On an unknown date, the patient experienced BLOOD GLUCOSE FLUCTUATION (blood sugar fluctuated and became unmanageable), INFLUENZA LIKE ILLNESS (flu like symptoms) and HEADACHE (headache). The patient was treated with IBUPROFEN for Headache, at a dose of 1 dosage form. At the time of the report, BLOOD GLUCOSE FLUCTUATION (blood sugar fluctuated and became unmanageable), INFLUENZA LIKE ILLNESS (flu like symptoms) and HEADACHE (headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   .
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Fatigue, Headache, Pyrexia
Clinical narrative: Feeling tired and fatigued in the evening after receiving 1st dose; Fever; Headache; Reporting joint pain in her whole body that is unusual and started next day; This spontaneous case was reported by a consumer and describes the occurrence of FATIGUE (Feeling tired and fatigued in the evening after receiving 1st dose), PYREXIA (Fever), HEADACHE (Headache) and ARTHRALGIA (Reporting joint pain in her whole body that is unusual and started next day) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 038A21A) for COVID-19 vaccination.     Concurrent medical conditions included Pre-diabetes.    On 16-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 16-Mar-2021, the patient experienced FATIGUE (Feeling tired and fatigued in the evening after receiving 1st dose), PYREXIA (Fever), HEADACHE (Headache) and ARTHRALGIA (Reporting joint pain in her whole body that is unusual and started next day). The patient was treated with IBUPROFEN (ADVIL [IBUPROFEN]) at an unspecified dose and frequency. At the time of the report, FATIGUE (Feeling tired and fatigued in the evening after receiving 1st dose), PYREXIA (Fever), HEADACHE (Headache) and ARTHRALGIA (Reporting joint pain in her whole body that is unusual and started next day) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications include pre-diabetes medications.